Investor's Business Daily on MSN17h
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Cantor Fitzgerald maintains NBIX overweight with $170 target
Cantor Fitzgerald reaffirmed its Overweight rating on Neurocrine Biosciences stock (NASDAQ:NBIX) with a consistent price target of $170.00. Currently trading at $150.51, the stock has shown strong ...
The Canadian Press on MSN16h
Navy commander relieved of his duty mid-deployment over 'loss of confidence'
OTTAWA - A commander of a patrol frigate in the Royal Canadian Navy has been relieved of his duty mid-deployment due to what ...